1. In Vivo
  2. >>Innovation

Data, AI And Machine Learning Are Propelling Clinical Trials Data Analysis To New Heights

 
• By Ashley Yeo

The quality of clinical trials and data analysis have come a long way in the past 10 years – and even in the past three, says Christian Hebenstreit of Medidata, the cloud-based platform that supports pharma and medtech companies through clinical studies ahead of their commercial uptake. The buzzwords of the fairly recent past are now being applied as real tools in the clinical trials arena, and look set to transform the sector.

The London arm of Medidata NEXT, the seven-venue awareness event for clinical trials professionals around the globe, is humming with industry players keen to hear how they can use Medidata Solutions Inc.'s Clinical Cloud tool, which combines science and the operation of clinical trials. At the podium, US product development executive Dave Metz is explaining the MEDS (Medidata Enterprise Data Store) element of the offering: the repository of clinical and operational data that are the basis of clinical process decision-making.

Metz's tone is irrepressibly upbeat: Medidata's service offerings to clinical clients are increasing in speed and quality across the industry....

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Innovation

Rising Leaders 2025: Kerry Benenato Champions The ‘Impossible’ In RNA Therapeutics

 
• By David Wild

From solving delivery challenges for Moderna's COVID-19 vaccine to pioneering the next generation of programmable medicines, the 2025 Rising Leader provides mid-career reflections.

As Pricing Pressures Mount, Biopharma Turns To AI To Reduce Trial Failure Rates

 
• By David Wild

With drug pricing policies potentially squeezing industry margins, companies are increasingly turning to AI-driven trial optimization to rescue sub-optimal studies and accelerate development timelines.

How Annexon Reclaimed Its Geographic Atrophy Program After Phase II Miss

The biotech's C1q inhibitor, vonaprument, preserved vision but missed the primary Phase II endpoint on lesion growth. The stakes are high for a Phase III with a different primary endpoint.

Rising Leaders 2025: Noam Solomon’s Quest To Create A ‘Google Maps’ Of the Immune System

 
• By David Wild

The mathematician-turned-CEO is building an atlas of clinical immune biology to revolutionize precision medicine.

More from In Vivo

The Rise In China Deals: How International Biopharma Is Turning To China For Innovation

 
• By Joseph Haas, Mary Jo Laffler, and Nancy Pham

The rapid growth of Chinese biopharmas has led to increased dealmaking with the US and Europe, but that could be stifled by a potential new Trump Administration policy.

Deals In Depth: August 2025

 
• By Deanna Kamienski and Maureen Riordan

Seven $1bn+ alliances were penned in August, and two exceeded $2bn.

As Pricing Pressures Mount, Biopharma Turns To AI To Reduce Trial Failure Rates

 
• By David Wild

With drug pricing policies potentially squeezing industry margins, companies are increasingly turning to AI-driven trial optimization to rescue sub-optimal studies and accelerate development timelines.